| Name | Title | Contact Details |
|---|
On Assignment, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Clear skin can be life-changing, but it`s not easy to see a dermatologist. At Curology, we provide prescription medications custom-formulated for each patient`s skin and shipped directly to their door. We tailor the entire Curology experience specifically for patients with acne and anti-aging concerns, allowing us to provide incredibly personalized, effective and affordable care at scale. We`ve assembled a committed team of dermatology providers and created a secure online platform, bringing professional acne care and prescription treatment to tens of thousands of people who wouldn`t otherwise be able to access or afford it. Curology helps people see tremendous, long-term improvements previously accessible only to a small percentage of the population. Our formulas are already on tens of thousands of sinks across the US. Our technology enables 1:1 chats with real dermatology providers and lets users to share their journeys with an engaged and growing community. Members can upload photos and track their progress over SMS, as well as browse and post digital postcards to share victories and encourage others. Curology is headquartered in the beautiful Hayes Valley neighborhood of San Francisco.
Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products.
SWIFT COUNTY BENSON HOSP is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Benson, MN. To find more information about SWIFT COUNTY BENSON HOSP, please visit www.scbh.org
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.